Profile data is unavailable for this security.
About the company
Dali Pharmaceutical Co Ltd is a China-based company principally involved in the production and sales of Chinese and western medicine injections. The Company’s main products include Xingnaojing injections and Shenmai injections. The other products include astragalus injections and mycorrhizal injections. Through its subsidiaries, the Company is also involved in the lease of offices and factory buildings, as well as the investment of equity.
- Revenue in CNY (TTM)61.64m
- Net income in CNY-24.38m
- Incorporated1996
- Employees272.00
- LocationDali Pharmaceutical Co LtdNo.118, Huancheng West Road, XiaguanDALI 671000ChinaCHN
- Phone+86 8 728880055
- Fax+86 8 728880055
- Websitehttp://www.daliyaoye.cn/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dali Pharmaceutical Co Ltd | 61.64m | -24.38m | 817.28m | 272.00 | -- | 2.26 | -- | 13.26 | -0.111 | -0.111 | 0.2806 | 1.64 | 0.1347 | 1.15 | 10.58 | 226,632.80 | -5.33 | -2.31 | -6.29 | -2.77 | 2.77 | 65.39 | -39.55 | -7.00 | 2.81 | -- | 0.052 | -- | -34.06 | -26.30 | -13.16 | -- | 16.34 | -- |
| Hangzhou Tianmushan Phrmtcl ntrprs C Ltd | 160.35m | -14.51m | 1.14bn | 380.00 | -- | 34.23 | -- | 7.14 | -0.1192 | -0.1192 | 1.32 | 0.2746 | 0.4537 | 2.29 | 3.43 | 421,978.40 | -4.39 | -6.93 | -22.04 | -18.92 | 36.69 | 33.95 | -9.69 | -16.42 | 0.4497 | -1.95 | 0.6938 | -- | 11.82 | -19.42 | 43.35 | -- | -24.89 | -- |
| Shaanxi Kanghui Pharmaceutical Co Ltd | 605.28m | -73.67m | 1.59bn | 952.00 | -- | 1.75 | -- | 2.63 | -0.7376 | -0.7376 | 6.06 | 9.12 | 0.292 | 1.86 | 2.74 | 635,795.70 | -4.81 | -0.1562 | -7.31 | -0.1991 | 27.93 | 40.00 | -16.47 | -0.4907 | 0.8304 | -0.9527 | 0.4169 | 95.15 | 36.92 | 12.37 | 58.52 | -- | 66.95 | -- |
| Jiangsu gdk Biotechnology Co Ltd | 52.65m | -113.37m | 1.88bn | 451.00 | -- | 1.43 | -- | 35.80 | -0.9188 | -0.9188 | 0.427 | 10.69 | 0.0321 | 0.4049 | 0.5195 | 116,733.70 | -6.92 | 3.30 | -8.09 | 4.84 | 51.66 | 75.56 | -215.35 | 12.58 | 2.67 | -- | 0.0433 | 32.60 | -57.74 | -- | -270.88 | -- | 54.07 | -- |
| Qinghai Spring Medicinl Rsrcs Tech CoLTD | 251.20m | -287.99m | 1.93bn | 173.00 | -- | 1.69 | -- | 7.67 | -0.4915 | -0.4915 | 0.4298 | 1.94 | 0.1843 | 0.5809 | 4.25 | 1,452,016.00 | -21.01 | -11.25 | -21.83 | -11.55 | 40.40 | 23.44 | -113.97 | -129.81 | 7.06 | -0.9897 | 0.0114 | -- | 33.52 | -8.48 | 6.85 | -- | -20.83 | -- |
Data as of Nov 15 2024. Currency figures normalised to Dali Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
0.00%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Western Leadbank Fund Management Co., Ltdas of 30 Jun 2024 | 0.00 | 0.00% |
| Hongde Fund Management Co., Ltd.as of 30 Jun 2024 | 0.00 | 0.00% |
| Lion Fund Management Co., Ltd.as of 30 Jun 2024 | 0.00 | 0.00% |
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
